Predictive values of miR‑129 and miR‑139 for efficacy on patients with prostate cancer after chemotherapy and prognostic correlation

Hu,Zhongchun; Guo,Junjie; Zhao,Ming; Jiang,Tao; Yang,Xiaofeng

doi:10.3892/ol.2019.10950

Predictive values of miR‑129 and miR‑139 for efficacy on patients with prostate cancer after chemotherapy and prognostic correlation

Authors:
- Zhongchun Hu
- Junjie Guo
- Ming Zhao
- Tao Jiang
- Xiaofeng Yang
View Affiliations

Affiliations: Department of Urological Surgery, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China, Department of Urological Surgery, School of Medical Technology, Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China, Department of Urological Surgery, School of Pathology, Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China
Published online on: October 2, 2019 https://doi.org/10.3892/ol.2019.10950
Pages: 6187-6195
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Predictive values of miR‑129 and miR‑139 for efficacy on patients with prostate cancer (PC) after chemotherapy and prognostic correlation were explored. Eighty‑four patients with PC undergoing chemotherapy in The Third Affiliated Hospital of Qiqihar Medical University from January 2016 to January 2017 were enrolled as the observation group treated with DP regimen, and further 100 healthy individuals undergoing physical examination were enrolled as the control group. RT‑qPCR was used to detect expression of serum miR‑129 and miR‑139. According to the clinical efficacy after treatment, patients with complete remission (CR) and partial remission (PR) were considered as a good curative effect group, whereas those with stable disease (SD) and progressive disease (PD) were considered as a poor curative effect group. In the observation group, miR‑129 and miR‑139 expression after treatment was significantly lower and higher, respectively, than that before treatment (P<0.05). After treatment, there were 15 patients with CR, 30 with PR, 26 with SD, and 13 with PD in the observation group. Before treatment, compared with the poor curative effect group, patients in the good curative effect group had significantly higher miR‑129 expression but significantly lower miR‑139 expression (P<0.05). The overall survival rate (OSR) of patients was 64.29%. The survival of patients in the miR‑129 high expression group was significantly better than that in the miR‑129 low expression group (P=0.001), whereas the survival in the miR‑139 low expression group was significantly better than that in the miR‑139 high expression group (P=0.012). According to multivariate Cox regression analysis, Gleason score, prostate specific antigen (PSA), bone metastasis, TNM staging, miR‑129, and miR‑139 were independent prognostic factors affecting patients. In conclusion, miR‑129 and miR‑139 are expected to be potential indicators for the diagnosis, prognosis, and efficacy prediction of PC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, et al: Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 67:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
5	Jonas S and Izaurralde E: Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 16:421–433. 2015. View Article : Google Scholar : PubMed/NCBI
6	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
7	Romaine SP, Tomaszewski M, Condorelli G and Samani NJ: MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart. 101:921–928. 2015. View Article : Google Scholar : PubMed/NCBI
8	Cammaerts S, Strazisar M, De Rijk P and Del Favero J: Genetic variants in microRNA genes: Impact on microRNA expression, function, and disease. Front Genet. 6:1862015. View Article : Google Scholar : PubMed/NCBI
9	Liu K, Huang J, Ni J, Song D, Ding M, Wang J, Huang X and Li W: MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle. 16:578–587. 2017. View Article : Google Scholar : PubMed/NCBI
10	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
11	Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, et al: MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol. 59:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
12	Zhao G, Zhou X, Fang T, Hou Y and Hu Y: Hyaluronic acid promotes the expression of progesterone receptor membrane component 1 via epigenetic silencing of miR-139-5p in human and rat granulosa cells. Biol Reprod. 91:1162014. View Article : Google Scholar : PubMed/NCBI
13	Amemiya Y, Wallis CJ, Benatar T, Kobylecky E, Sugar L, Sherman C, Nam R and Seth AK: Abstract A079: MicroRNA-139 regulates prostate cancer aggressiveness by targeting IGF1R. Cancer Res 78 (16 Supplement). A079. 2018.
14	Conley-LaComb MK, Semaan L, Singareddy R, Li Y, Heath EI, Kim S, Cher ML and Chinni SR: Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis. Mol Cancer. 15:682016. View Article : Google Scholar : PubMed/NCBI
15	Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J and Goldstraw P; International Staging Committee and Participating Institutions, : The International Association for the Study of Lung Cancer Staging Project: Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 4:792–801. 2009. View Article : Google Scholar : PubMed/NCBI
16	Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, et al: A contemporary prostate cancer grading system: A validated alternative to the Gleason score. Eur Urol. 69:428–435. 2016. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Higano C: Androgen deprivation therapy: Monitoring and managing the complications. Hematol Oncol Clin North Am. 20:909–923. 2006. View Article : Google Scholar : PubMed/NCBI
19	Agarwal V, Subtelny AO, Thiru P, Ulitsky I and Bartel DP: Predicting microRNA targeting efficacy in Drosophila. Genome Biol. 19:1522018. View Article : Google Scholar : PubMed/NCBI
20	Zuo Y, Li Y, Zhou Z, Ma M and Fu K: Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer. Biomed Pharmacother. 95:922–928. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zhang HD, Jiang LH, Sun DW, Li J and Tang JH: MiR-139-5p: Promising biomarker for cancer. Tumour Biol. 36:1355–1365. 2015. View Article : Google Scholar : PubMed/NCBI
22	Xu S, Yi XM, Zhou WQ, Cheng W, Ge JP and Zhang ZY: Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer. Int J Clin Exp Pathol. 8:14335–14344. 2015.PubMed/NCBI
23	Pang C, Liu M, Fang W, Guo J, Zhang Z, Wu P, Zhang Y and Wang J: MiR-139-5p is increased in the peripheral blood of patients with prostate cancer. Cell Physiol Biochem. 39:1111–1117. 2016. View Article : Google Scholar : PubMed/NCBI
24	Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, et al COU-AA-301 Investigators, : Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13:983–992. 2012. View Article : Google Scholar : PubMed/NCBI
25	Mahammedi H, Planchat E, Pouget M, Durando X, Curé H, Guy L, Van-Praagh I, Savareux L, Atger M, Bayet-Robert M, et al: The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: A Pilot Phase II Study. Oncology. 90:69–78. 2016. View Article : Google Scholar : PubMed/NCBI
26	Wachter S, Gerstner N, Goldner G, Pötzi R, Wambersie A and Pötter R: Rectal sequelae after conformal radiotherapy of prostate cancer: Dose-volume histograms as predictive factors. Radiother Oncol. 59:65–70. 2001. View Article : Google Scholar : PubMed/NCBI
27	Dezhong L, Xiaoyi Z, Xianlian L, Hongyan Z, Guohua Z, Bo S, Shenglei Z and Lian Z: miR-150 is a factor of survival in prostate cancer patients. J BUON. 20:173–179. 2015.PubMed/NCBI